Combination therapy with tamsulosin and solifenacin in the treatment of patients with severe lower urinary tract symptoms associated with benign prostatic enlargement Case report
Article Sidebar
Published:
Mar 31, 2025
Keywords:
benign prostate hyperplasia, overactive bladder, lower urinary tract symptoms, solifenacin, tamsulosin
Main Article Content
Abstract
The combination of solifenacin and tamsulosin represents a promising therapeutic option for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia, particularly in cases of coexisting severe storage phase symptoms or overactive bladder syndrome. Combined therapy allows for the simultaneous reduction of lower urinary tract symptoms from both storage and voiding phases, which is crucial for improving patients’ quality of life. An additional advantage is the single-tablet formulation of the solifenacin and tamsulosin, which may enhance patient compliance and treatment efficacy.
Article Details
How to Cite
Ślusarczyk, A. (2025). Combination therapy with tamsulosin and solifenacin in the treatment of patients with severe lower urinary tract symptoms associated with benign prostatic enlargement. Medycyna Faktow (J EBM), 18(1(66), 161-164. https://doi.org/10.24292/01.MF.0125.24
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-12.
2. Sakalis V, Sfiggas V, Vouros I et al. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study. Int J Urol. 2018; 25(8): 737-45.
3. Su YT, Chen HL, Teoh JYC et al. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients – a network meta-analysis. BMC Urol. 2023; 23(1): 154.
4. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61(1): 37-49.
5. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) 2025.
6. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5): 565-78.
7. Lenfant L, Pinar U, Roupret M et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol. 2023; 209(2): 314-24.
8. Nichol MB, Knight TK, Wu J et al. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009; 181(5): 2214-21.
9. Djavan B, Fong YK, Harik M et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004; 64(6): 1144-8.
10. Drake MJ, Oelke M, Snijder R et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One. 2017; 12(2): e0170726.
11. Chancellor MB, Migliaccio-Walle K, Bramley TJ et al. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013; 35(11): 1744-51.
12. Kwon T, Oh TH, Choi S et al. Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality. J Korean Med Sci. 2017; 32(9): 1491-5.
13. Michel MC, Neumann HG, Mehlburger L et al. Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? BJU Int. 2001; 87(1): 31-4.
14. Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-70.
2. Sakalis V, Sfiggas V, Vouros I et al. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study. Int J Urol. 2018; 25(8): 737-45.
3. Su YT, Chen HL, Teoh JYC et al. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients – a network meta-analysis. BMC Urol. 2023; 23(1): 154.
4. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61(1): 37-49.
5. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) 2025.
6. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5): 565-78.
7. Lenfant L, Pinar U, Roupret M et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol. 2023; 209(2): 314-24.
8. Nichol MB, Knight TK, Wu J et al. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009; 181(5): 2214-21.
9. Djavan B, Fong YK, Harik M et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004; 64(6): 1144-8.
10. Drake MJ, Oelke M, Snijder R et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One. 2017; 12(2): e0170726.
11. Chancellor MB, Migliaccio-Walle K, Bramley TJ et al. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013; 35(11): 1744-51.
12. Kwon T, Oh TH, Choi S et al. Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality. J Korean Med Sci. 2017; 32(9): 1491-5.
13. Michel MC, Neumann HG, Mehlburger L et al. Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? BJU Int. 2001; 87(1): 31-4.
14. Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-70.